Screening for fragile X is cost effective and accurateBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7102.205i (Published 26 July 1997) Cite this as: BMJ 1997;315:205
- Caroline White
Screening for the fragile X syndrome is both accurate and cost effective and should now be considered for inclusion in a national screening programme, concludes a new report commissioned by the NHS Executive's research and development programme on health technology assessment (Journal of Medical Screening 1997;4:60-94).
DNA testing to screen for the disorder is now technically feasible. However, although the technology has been available for some time, there has been some reluctance to …